Vandria SA, a clinical stage biotech company developing small molecule therapeutics to restore mitochondrial function and reduce inflammation for the treatment of age-related and chronic diseases, today announces topline results from its first-in-human clinical trial of its lead Central Nervous System (CNS) compound VNA-318.
VNA-318 is a first-in-class, orally bioavailable, and brain-penetrant small molecule targeting a novel protein with a dual mode of action (MoA). Initially, VNA-318 is being developed to address the major unmet medical needs facing patients with Alzheimer’s disease: cognitive impairment and the debilitating loss of function associated with it. Given its broad MoA, VNA-318 has potential to treat other CNS diseases.
